DTIL Similar Chart Price Prediction
The price of DTIL is predicted to go up 6.56%, based on the high correlation periods with FISI. The similarity of these two price pattern on the periods is 90.61%.
DTIL
FISI
Up: 6.56%Similarity: 90.61%
DTIL Revenue Forecast
DTIL EPS Forecast
DTIL FAQs
What is bull’s view on DTIL?
What is bear's view on DTIL?
What is DTIL revenue forecast for next quarter？
What is DTIL eps forecast for next quarter？
DTIL Analyst's Forecast
Kostas Biliouris
BMO Capital
Hold → Buy
Price Target
$34
Upside
+496.49%
BMO Capital upgraded Precision BioSciences to Outperform from Market Perform with an unchanged price target of $34 alter iECURE announced clinical data in ornithine transcarbamylase using Precision's in vivo gene editor. The data appear "very promising," providing early clinical validation for Arcus, the analyst tells investors in a research note. As such, BMO sees a 65% probability for Precisions in vivo hepatitis B virus program to deliver acceptable safety and strong efficacy, driving 100%-200% upside in the shares. It believes Precision's risk/reward is favorable at current share levels.